TNDM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tandem Diabetes Care Inc (TNDM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's transition to a pharmacy model, strong hedge fund buying, improved financial performance, and positive analyst sentiment suggest significant growth potential. While the stock is currently trading slightly lower in pre-market, the overall outlook remains favorable for long-term investment.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram of 0.902, and an RSI of 68.492, which is neutral but nearing overbought levels. Key resistance levels are at R1: 27.863 and R2: 30.681, while support levels are at S1: 18.741 and S2: 15.923. The technical indicators suggest a bullish trend with potential for further upside.
Hedge funds are significantly increasing their positions, with buying up 870.81% last quarter.
Analysts have raised price targets, with some upgrades to Buy and targets as high as $
Recent $265 million convertible senior notes offering indicates strong market demand and provides additional capital for growth.
Q4 financials showed a 3% YoY revenue increase and better-than-expected sales performance.
Insiders are neutral with no significant trading activity.
Net income and EPS have declined YoY, reflecting profitability challenges.
Competitive pressures and reliance on reduced R&D spending create near-term uncertainty.
In Q4 2025, revenue increased by 2.74% YoY to $290.4 million, gross margin improved to 57.67% (+3.52% YoY), but net income dropped to -$589,000 (-178.01% YoY) and EPS fell to -$0.01 (-200% YoY). Despite profitability challenges, the company is showing signs of operational improvement.
Analysts have shown increased optimism, with multiple firms raising price targets and upgrading ratings. Notable upgrades include Lake Street raising the target to $50 and Barclays increasing the target to $56, citing strong growth potential from the pharmacy model transition and improved margins.
